<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33669483</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>19</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Comparison of Monoclonal Gammopathies Linked to Poliovirus or Coxsackievirus vs. Other Infectious Pathogens.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">438</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells10020438</ELocationID><Abstract><AbstractText>Chronic stimulation by infectious pathogens or self-antigen glucosylsphingosine (GlcSph) can lead to monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). Novel assays such as the multiplex infectious antigen microarray (MIAA) and GlcSph assays, permit identification of targets for &gt;60% purified monoclonal immunoglobulins (Igs). Searching for additional targets, we selected 28 purified monoclonal Igs whose antigen was not represented on the MIAA and GlcSph assays; their specificity of recognition was then analyzed using microarrays consisting of 3760 B-cell epitopes from 196 pathogens. The peptide sequences PALTAVETG and PALTAAETG of the VP1 coat proteins of human poliovirus 1/3 and coxsackievirus B1/B3, respectively, were specifically recognized by 6/28 monoclonal Igs. Re-analysis of patient cohorts showed that purified monoclonal Igs from 10/155 MGUS/SM (6.5%) and 3/147 MM (2.0%) bound to the PALTAVETG or PALTAAETG epitopes. Altogether, PALTAV/AETG-initiated MGUS are not rare and few seem to evolve toward myeloma.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harb</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CRCINA, Inserm, Universit&#xe9; de Nantes, Universit&#xe9; d'Angers, 44000 Nantes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de Recherche en Transplantation et Immunologie UMR1064, Inserm, Universit&#xe9; de Nantes, 44000 Nantes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire de Biochimie, CHU de Nantes, 44000 Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mennesson</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>CRCINA, Inserm, Universit&#xe9; de Nantes, Universit&#xe9; d'Angers, 44000 Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lepetit</LastName><ForeName>Cassandra</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CRCINA, Inserm, Universit&#xe9; de Nantes, Universit&#xe9; d'Angers, 44000 Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fourny</LastName><ForeName>Maeva</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CRCINA, Inserm, Universit&#xe9; de Nantes, Universit&#xe9; d'Angers, 44000 Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Louvois</LastName><ForeName>Margaux</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CRCINA, Inserm, Universit&#xe9; de Nantes, Universit&#xe9; d'Angers, 44000 Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosseboeuf</LastName><ForeName>Adrien</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CRCINA, Inserm, Universit&#xe9; de Nantes, Universit&#xe9; d'Angers, 44000 Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allain-Maillet</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>CRCINA, Inserm, Universit&#xe9; de Nantes, Universit&#xe9; d'Angers, 44000 Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Decaux</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Internal Medicine, CHU de Rennes, 35000 Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreau</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratoire de Biochimie, CHU de Rennes, 35000 Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tallet</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratoire de PGMC, CHU de Tours, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piver</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7101-0121</Identifier><AffiliationInfo><Affiliation>Laboratoire de Biochimie, CHU de Tours, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm UMR1259, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreau</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hematology Department, CHU Nantes, 44000 Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salle</LastName><ForeName>Val&#xe9;ry</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Internal Medicine, CHU Amiens, 80000 Amiens, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bigot-Corbel</LastName><ForeName>Edith</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-2760-8740</Identifier><AffiliationInfo><Affiliation>CRCINA, Inserm, Universit&#xe9; de Nantes, Universit&#xe9; d'Angers, 44000 Nantes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire de Biochimie, CHU de Nantes, 44000 Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermouet</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5444-4406</Identifier><AffiliationInfo><Affiliation>CRCINA, Inserm, Universit&#xe9; de Nantes, Universit&#xe9; d'Angers, 44000 Nantes, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire d'H&#xe9;matologie, CHU Nantes, 44000 Nantes, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="N">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010265" MajorTopicYN="N">Paraproteinemias</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MGUS</Keyword><Keyword MajorTopicYN="N">antigen specificity</Keyword><Keyword MajorTopicYN="N">coxsackievirus</Keyword><Keyword MajorTopicYN="N">infection</Keyword><Keyword MajorTopicYN="N">monoclonal gammopathy</Keyword><Keyword MajorTopicYN="N">monoclonal immunoglobulin</Keyword><Keyword MajorTopicYN="N">multiple myeloma</Keyword><Keyword MajorTopicYN="N">pathogen</Keyword><Keyword MajorTopicYN="N">poliovirus</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest. The funders had no role in the design of the study; in analyses or interpretation of data; in the writing of the manuscript or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>6</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33669483</ArticleId><ArticleId IdType="pmc">PMC7922508</ArticleId><ArticleId IdType="doi">10.3390/cells10020438</ArticleId><ArticleId IdType="pii">cells10020438</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dhodapkar M.V. MGUS to myeloma: A mysterious gammopathy of underexplored significance. Blood. 2016;128:2599&#x2013;2606. doi: 10.1182/blood-2016-09-692954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-09-692954</ArticleId><ArticleId IdType="pmc">PMC5146746</ArticleId><ArticleId IdType="pubmed">27737890</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyle R.A., Larson D.R., Therneau T.M., Dispenzieri A., Kumar S., Cerhan J.R., Rajkumar S.V. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. N. Engl. J. Med. 2018;378:241&#x2013;249. doi: 10.1056/NEJMoa1709974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1709974</ArticleId><ArticleId IdType="pmc">PMC5852672</ArticleId><ArticleId IdType="pubmed">29342381</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkumar S.V., Dimopoulos M.A., Palumbo A., Blade J., Merlini G., Mateos M.V., Kumar S., Hillengass J., Kastritis E., Richardson P., et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538&#x2013;e548. doi: 10.1016/S1470-2045(14)70442-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(14)70442-5</ArticleId><ArticleId IdType="pubmed">25439696</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermouet S., Corre I., Gassin M., Bigot-Corbel E., Sutton C.A., Casey J.W. Hepatitis C virus, human herpesvirus 8 and the development of plasma-cell leukemia. N. Engl. J. Med. 2003;348:178&#x2013;179. doi: 10.1056/NEJM200301093480219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200301093480219</ArticleId><ArticleId IdType="pubmed">12519936</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigot-Corbel E., Gassin M., Corre I., Le Carrer D., Delaroche O., Hermouet S. Hepatitis C virus (HCV) infection, monoclonal immunoglobulin specific for HCV core protein and plasma-cell malignancy. Blood. 2008;112:4357&#x2013;4358. doi: 10.1182/blood-2008-07-167569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-07-167569</ArticleId><ArticleId IdType="pubmed">18988883</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosseboeuf A., Feron D., Tallet A., Rossi C., Charlier C., Garderet L., Caillot D., Moreau P., Cardo-Vila M., Pasqualini R., et al. Monoclonal IgG in MGUS and multiple myeloma target infectious pathogens. J. Clin Investig. Insight. 2017;2:19. doi: 10.1172/jci.insight.95367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.95367</ArticleId><ArticleId IdType="pmc">PMC5841870</ArticleId><ArticleId IdType="pubmed">28978808</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair S., Branagan A.R., Liu J., Boddupalli C.S., Mistry P.K., Dhodapkar M.V. Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. N. Engl. J. Med. 2016;374:555&#x2013;561. doi: 10.1056/NEJMoa1508808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1508808</ArticleId><ArticleId IdType="pmc">PMC4804194</ArticleId><ArticleId IdType="pubmed">26863356</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair S., Sng J., Sekhar Boddupalli C., Seckinger A., Chesi M., Fulciniti M., Zhang L., Rauniyar N., Lopez M., Neparidze N., et al. Antigen-mediated regulation in monoclonal gammopathies and myeloma. J. Clin. Investig. Insight. 2018;3:e98259. doi: 10.1172/jci.insight.98259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.98259</ArticleId><ArticleId IdType="pmc">PMC5931125</ArticleId><ArticleId IdType="pubmed">29669929</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosseboeuf A., Mennesson N., Allain-Maillet S., Tallet A., Piver E., Moreau C., Moreau P., Lehours P., M&#xe9;graud F., Salle V., et al. Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine or Epstein-Barr Virus EBNA-1. Cancers. 2020;12:1254. doi: 10.3390/cancers12051254.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12051254</ArticleId><ArticleId IdType="pmc">PMC7281552</ArticleId><ArticleId IdType="pubmed">32429322</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosseboeuf A., Seillier C., Mennesson N., Allain-Maillet S., Fourny M., Tallet A., Piver E., Lehours P., M&#xe9;graud F., Berthelot L., et al. Analysis of the targets and glycosylation of monoclonal IgAs from MGUS and myeloma patients. Front. Immunol. 2020;11:854. doi: 10.3389/fimmu.2020.00854. eCollection 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00854</ArticleId><ArticleId IdType="pmc">PMC7266999</ArticleId><ArticleId IdType="pubmed">32536913</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair S., Bar N., Xu M.L., Dhodapkar M., Mistry P.K. Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. Mol. Genet. Metab. 2020;129:286&#x2013;291. doi: 10.1016/j.ymgme.2020.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymgme.2020.01.009</ArticleId><ArticleId IdType="pmc">PMC8223251</ArticleId><ArticleId IdType="pubmed">32044242</ArticleId></ArticleIdList></Reference><Reference><Citation>Panfilio S., D&#x2019;Urso P., Annechini G., D&#x2019;Elia G.M., De Angelis F., Stefanizzi C., Pulsoni A. Regression of a case of Multiple Myeloma with antiviral treatment in a patient with chronic HCV infection. Leuk. Res. Rep. 2013;2:39&#x2013;40. doi: 10.1016/j.lrr.2013.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lrr.2013.01.002</ArticleId><ArticleId IdType="pmc">PMC3850378</ArticleId><ArticleId IdType="pubmed">24371776</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a A.R., Linares M., Mennesson N., Sanchez-Vega B., Sanchez R., Fernandez R.A., Bigot-Corbel E., Hermouet S., Lopez J.M. The Role of Hepatitis C Virus in the Development of Multiple Myeloma: A Case Study. Blood. 2018;132:5592. doi: 10.1182/blood-2018-99-112842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-99-112842</ArticleId></ArticleIdList></Reference><Reference><Citation>Feron D., Charlier C., Gourain V., Garderet L., Coste-Burel M., Le Pape P., Weigel P., Jacques Y., Hermouet S., Bigot-Corbel E. Multiplexed infectious protein microarray immunoassay suitable for the study of the specificity of monoclonal immunoglobulins. Anal. Biochem. 2013;433:202&#x2013;209. doi: 10.1016/j.ab.2012.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2012.10.012</ArticleId><ArticleId IdType="pubmed">23103342</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosseboeuf A., Allain S., Mennesson N., Tallet A., Rossi C., Garderet L., Caillot D., Moreau P., Piver E., Girodon F., et al. Pro-inflammatory state in MGUS and Myeloma is characterized by low sialylation of pathogen-specific and other monoclonal and polyclonal immunoglobulin G. Front. Immunol. 2017;8:1347. doi: 10.3389/fimmu.2017.01347. eCollection 2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01347</ArticleId><ArticleId IdType="pmc">PMC5653692</ArticleId><ArticleId IdType="pubmed">29098000</ArticleId></ArticleIdList></Reference><Reference><Citation>Nooij F.J., Van der Sluijs-Gelling A.J., Jol-Van der Zijde C.M., Van Tol M.J., Haas H., Radl J. Immunoblotting techniques for the detection of low level homogeneous immunoglobulin components in serum. J. Immunol. Methods. 1990;134:273&#x2013;281. doi: 10.1016/0022-1759(90)90389-D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-1759(90)90389-D</ArticleId><ArticleId IdType="pubmed">2254671</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun W., Abraham R. Modified diffusion blotting for rapid and efficient protein transfer with PhastSystem. Electrophoresis. 1989;10:249&#x2013;253. doi: 10.1002/elps.1150100406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/elps.1150100406</ArticleId><ArticleId IdType="pubmed">2743968</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmonds P., Gorbalenya A.E., Harvala H., Hovi T., Knowles N.J., Lindberg A.M., Oberste M.S., Palmenberg A.C., Reuter G., Skern T., et al. Recommendations for the nomenclature of enteroviruses and rhinoviruses. Arch. Virol. 2020;165:793&#x2013;797. doi: 10.1007/s00705-019-04520-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-019-04520-6</ArticleId><ArticleId IdType="pmc">PMC7024059</ArticleId><ArticleId IdType="pubmed">31980941</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste M.S., Maher K., Kilpatrick D.R., Pallansch M.A. Molecular evolution of the human enteroviruses: Correlation of serotype with VP1 sequence and application to picornavirus classification. J. Virol. 1999;73:1941&#x2013;1948. doi: 10.1128/JVI.73.3.1941-1948.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.73.3.1941-1948.1999</ArticleId><ArticleId IdType="pmc">PMC104435</ArticleId><ArticleId IdType="pubmed">9971773</ArticleId></ArticleIdList></Reference><Reference><Citation>Salk J.E. Poliomyelitis vaccination in the fall of 1956. Am. J. Public Health Nations Health. 1957;47:1&#x2013;18. doi: 10.2105/AJPH.47.1.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.47.1.1</ArticleId><ArticleId IdType="pmc">PMC1551087</ArticleId><ArticleId IdType="pubmed">13381837</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabin A.B., Boulger L.R. History of Sabin attenuated poliovirus oral live vaccine strains. J. Biol. Stand. 1973;1:115&#x2013;118. doi: 10.1016/0092-1157(73)90048-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-1157(73)90048-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabin A.B., Ramos-Alvarez M., Alvarez-Amezquita J., Pelon W., Michaels R.H., Spigland I., Koch M.A., Barnes J.M., Rhim J.S. Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. JAMA. 1960;173:1521&#x2013;1526. doi: 10.1001/jama.1960.03020320001001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1960.03020320001001</ArticleId><ArticleId IdType="pubmed">14440553</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 2005;59:587&#x2013;635. doi: 10.1146/annurev.micro.58.030603.123625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.micro.58.030603.123625</ArticleId><ArticleId IdType="pubmed">16153180</ArticleId></ArticleIdList></Reference><Reference><Citation>Signorini L., Barbi M., Matteelli A., Binda S., Did&#xf2; P., Caroppo S., Primache V., Pisani S., Messino C., Brunelli M., et al. Prevalence of anti-poliovirus type 1, 2 and 3 antibodies in unvaccinated Italian travelers. J. Travel. Med. 2004;11:34&#x2013;36. doi: 10.2310/7060.2004.13651.</Citation><ArticleIdList><ArticleId IdType="doi">10.2310/7060.2004.13651</ArticleId><ArticleId IdType="pubmed">14769285</ArticleId></ArticleIdList></Reference><Reference><Citation>Nijsten D., Carrillo-Santisteve P., Miglietta A., Ruitenberg J., Lopalco P.L. Is EU/EEA population protected from polio? Hum. Vaccin Immunother. 2015;11:2123&#x2013;2131. doi: 10.1080/21645515.2015.1016673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1016673</ArticleId><ArticleId IdType="pmc">PMC4635704</ArticleId><ArticleId IdType="pubmed">25898095</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevots D.R., Pascual F.B., Angellili M.L., Brayden R., Irigoyen M., Larussa P., Sawyer M., Baughman A.L., Pallansch M.A. Population immunity to polioviruses among preschool children from four urban underserved low income communities, United States, 1997&#x2013;2001. Pediatr. Infect. Dis. J. 2004;23:1130&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pubmed">15626951</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciandra I., Falasca F., Maida P., Tranquilli G., Di Carlo D., Mazzuti L., Melengu T., Giannelli G., Antonelli G., Turriziani O. Seroprevalence of group B Coxsackieviruses: Retrospective study in an Italian population. J. Med. Virol. 2020;92:3138&#x2013;3143. doi: 10.1002/jmv.26096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26096</ArticleId><ArticleId IdType="pubmed">32531866</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhodapkar M.V., Sexton R., Hoering A., Van Rhee F., Barlogie B., Orlowski R. Race-Dependent Differences in Risk, Genomics and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120. Clin. Cancer Res. 2020;26:5814&#x2013;5819. doi: 10.1158/1078-0432.CCR-20-2119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-20-2119</ArticleId><ArticleId IdType="pmc">PMC7679008</ArticleId><ArticleId IdType="pubmed">32816893</ArticleId></ArticleIdList></Reference><Reference><Citation>Manojlovic Z., Christofferson A., Liang W.S., Aldrich J., Washington M., Wong S., Rohrer D., Jewell S., Kittles R.A., Derome M., et al. Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases. PLoS Genet. 2017;13:e1007087. doi: 10.1371/journal.pgen.1007087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1007087</ArticleId><ArticleId IdType="pmc">PMC5699827</ArticleId><ArticleId IdType="pubmed">29166413</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazandjian D., Hill E., Hultcrantz M., Rustad E.H., Yellapantula V., Akhlaghi T., Korde N., Mailankody S., Dew A., Papaemmanuil E., et al. Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients. Blood Cancer J. 2019;9:15. doi: 10.1038/s41408-019-0177-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41408-019-0177-9</ArticleId><ArticleId IdType="pmc">PMC6361959</ArticleId><ArticleId IdType="pubmed">30718460</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Munoz M.E., Fuentes-Panana E.M. Beta and gamma human herpesviruses: Agonistic and antagonistic interactions with the host immune system. Front. Microbiol. 2017;8:2521. doi: 10.3389/fmicb.2017.02521.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.02521</ArticleId><ArticleId IdType="pmc">PMC5760548</ArticleId><ArticleId IdType="pubmed">29354096</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunce C.M., Drayson M.T. Dissecting racial disparities in multiple myeloma: Clues from differential immunoglobulin levels. Blood Cancer J. 2020;10:44. doi: 10.1038/s41408-020-0314-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41408-020-0314-5</ArticleId><ArticleId IdType="pmc">PMC7188885</ArticleId><ArticleId IdType="pubmed">32345975</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>